NCT03360721 2026-03-16
Apalutamide, Abiraterone Acetate, and Prednisone in Treating Participants With Metastatic Castration Resistant Prostate Cancer
M.D. Anderson Cancer Center
Phase 2 Terminated
Clinical Trials
14 trialsNCT04108208 2026-03-16
A Study of Apalutamide in Chinese Participants With Non Metastatic Castration Resistant Prostate Cancer (NM-CRPC)
Janssen Research & Development, LLC
Phase 4 Active not recruiting
NCT05751941 2026-03-16
Study of Sipuleucel-T With or Without Continuing New Hormonal Agents in Metastatic Prostate Cancer
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Recruiting
NCT03523442 2026-03-13
A Study of Androgen Receptor (AR) Antagonist Apalutamide in Chinese Participants With Metastatic Castration-Resistant Prostate Cancer
Janssen Research & Development, LLC
Phase 1 Active not recruiting
NCT04557059 2026-03-13
PRIMORDIUM
Janssen Pharmaceutica N.V., Belgium
Phase 3 Active not recruiting
NCT04662580 2026-03-13
ARX517
Janssen Research & Development, LLC
Phase 1 Active not recruiting
NCT05884398 2026-03-12
LIBERTAS
Janssen Research & Development, LLC
Phase 3 Active not recruiting
NCT05960578 2026-03-12
Golimumab and Apalutamide for the Treatment of Castration-Resistant Prostate Cancer, TRAMP Study
University of Washington
Phase 2 Active not recruiting
NCT02703623 2026-03-06
Abiraterone Acetate, Prednisone, and Apalutamide With or Without Ipilimumab or Cabazitaxel and Carboplatin in Treating Patients With Metastatic Castration-Resistant Prostate Cancer
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT06931340 2026-03-04
Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE Trial
Alliance for Clinical Trials in Oncology
Phase 3 Recruiting
NCT04423211 2026-03-02
Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging
Eastern Cooperative Oncology Group
Phase 3 Recruiting
NCT01171898 2026-02-24
Safety, Pharmacokinetic and Proof-of-Concept Study of ARN-509 (Apalutamide) in Castration-Resistant Prostate Cancer (CRPC)
Aragon Pharmaceuticals, Inc.
Phase 1/2 Completed
NCT04947254 2026-02-19
Androgen Ablation Therapy With or Without Niraparib After Radiation Therapy for the Treatment of High-Risk Localized or Locally Advanced Prostate Cancer
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT05521698 2026-02-17
Study to Determine Possible Effects of Apalutamide, Compared to Placebo, on EGFR Expression in Patients With Non-muscle Invasive Bladder Cancer
University of Wisconsin, Madison
Phase 1 Not yet recruiting